PATIENT GUIDE

GLP-1 Weight Loss Medications via Telehealth in Australia

Published 1 May 2026 · 11 min read · Updated regularly

GLP-1 receptor agonists have fundamentally changed the landscape of medical weight loss worldwide. Medications like semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound) are producing weight loss results that were previously only achievable through bariatric surgery — and they're doing it safely, under medical supervision, via a weekly injection. In Australia, specialist telehealth clinics are making these medications more accessible than ever before.

Understanding GLP-1 Receptor Agonists

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a naturally occurring hormone produced in the gut after eating. This hormone signals to the brain that you've eaten enough, slows the rate at which food moves through your stomach, and helps regulate blood sugar levels. The result is reduced appetite, increased satiety, and — when combined with dietary changes and physical activity — significant and sustained weight loss.

The landmark STEP trials published in the New England Journal of Medicine demonstrated that semaglutide 2.4mg (Wegovy) produced an average weight loss of approximately 15% of body weight over 68 weeks. Tirzepatide, a dual GIP/GLP-1 agonist, showed even greater efficacy in the SURMOUNT trials, with average weight loss of 20–22% of body weight at the highest dose.

To put these numbers in context: for a person weighing 120kg, a 20% reduction means losing approximately 24kg — a life-changing outcome that substantially reduces the risk of type 2 diabetes, cardiovascular disease, sleep apnoea, joint disease, and numerous other weight-related conditions.

Available GLP-1 Medications in Australia

The Therapeutic Goods Administration (TGA) has approved several GLP-1 receptor agonists for use in Australia:

Semaglutide (Ozempic): TGA-approved for type 2 diabetes. Available as a weekly subcutaneous injection in 0.25mg, 0.5mg, and 1mg doses. Frequently prescribed off-label for weight management. PBS-subsidised for patients with type 2 diabetes meeting specific criteria.

Semaglutide (Wegovy): TGA-approved specifically for chronic weight management. Higher dose (2.4mg weekly) than Ozempic. Currently available as a private prescription — not yet PBS-listed for weight management indication. Monthly cost for patients typically ranges from $300–$450.

Tirzepatide (Mounjaro): Dual GIP/GLP-1 receptor agonist. TGA-approved for type 2 diabetes with weight management indications under review. Available in doses from 2.5mg to 15mg weekly. Shows superior weight loss efficacy compared to semaglutide alone in head-to-head trials.

Liraglutide (Saxenda): Daily injection approved for weight management. Generally considered less effective than weekly semaglutide formulations but may suit patients who prefer a daily dosing schedule or who experience intolerable side effects from semaglutide.

Eligibility Criteria

Eligibility for GLP-1 weight loss medications in Australia generally requires:

BMI ≥ 30 kg/m² (classified as obese), or BMI ≥ 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, non-alcoholic fatty liver disease, or polycystic ovary syndrome.

Additional clinical considerations include: previous weight loss attempts (lifestyle modifications should generally be attempted first), cardiovascular risk profile, family history of medullary thyroid carcinoma (a contraindication for GLP-1 agonists), history of pancreatitis, current medications, mental health status, and pregnancy planning (GLP-1 agonists must be discontinued at least 2 months before conception).

Your prescribing GP will conduct a comprehensive assessment of all these factors during your initial consultation. The Australian guidelines align broadly with World Health Organization (WHO) recommendations for pharmacological weight management.

How Telehealth Weight Loss Consultations Work

Step 1 — Booking and intake: You book an appointment with a specialist weight loss telehealth clinic. Before your consultation, you complete detailed intake forms covering your medical history, current medications, previous weight loss attempts, dietary habits, physical activity, and goals. Many clinics use validated tools like the BMI calculator and metabolic health questionnaires.

Step 2 — Pre-consultation requirements: You'll need a recent blood pressure reading (validated home monitor readings are usually accepted), and baseline blood tests including fasting glucose/HbA1c, lipid profile, liver function tests, kidney function, and thyroid function. These can be done at any pathology collection centre with a request from your GP.

Step 3 — Video consultation (20–30 minutes): Your GP reviews your history, blood results, and eligibility. You discuss medication options, expected outcomes, potential side effects (primarily gastrointestinal — nausea, which typically resolves within the first 4–8 weeks), titration schedule, cost considerations, and lifestyle modifications to maximise results.

Step 4 — Prescription and supply: If appropriate, the GP issues an electronic prescription via eRx. You fill it at your local pharmacy. The medication requires refrigerated storage and is self-administered as a weekly subcutaneous injection — your GP or pharmacist will walk you through injection technique.

Step 5 — Ongoing management: Follow-up consultations every 4–6 weeks initially, extending to 8–12 weekly once stable. Dose titration typically follows a schedule: starting at the lowest dose and increasing every 4 weeks based on tolerability and response. Regular monitoring includes weight, blood pressure, blood glucose (if diabetic), and side effect assessment.

Managing Side Effects

The most common side effects of GLP-1 medications are gastrointestinal: nausea, reduced appetite (which is partly how they work), constipation or diarrhoea, and occasional vomiting. For most patients, these are mild to moderate and improve significantly within the first 4–8 weeks as the body adjusts.

Evidence-based strategies for managing GI side effects include: eating smaller, more frequent meals; avoiding high-fat and greasy foods during the titration phase; staying well hydrated; eating slowly; and using the gradual dose titration schedule rather than rushing to higher doses. Your telehealth GP will provide detailed guidance and can adjust the titration schedule if side effects are significant.

Rare but serious side effects include pancreatitis (seek immediate medical attention for severe persistent abdominal pain), gallbladder disease, and very rarely, allergic reactions. These risks are monitored through regular follow-up consultations — another reason why ongoing medical supervision is essential.

Why Specialist Telehealth Clinics Deliver Better Results

Weight loss is a medical intervention that requires ongoing support, monitoring, and adjustment. The difference between a successful weight management program and a failed one often comes down to the quality and consistency of medical follow-up.

Specialist telehealth clinics like Weight Loss GP Australia — part of the Telehealth Australia Group network — focus exclusively on medical weight management. The GPs consult on weight loss cases daily, understand the medications deeply, and can provide the kind of structured, evidence-based ongoing care that leads to better outcomes. They know when to adjust doses, how to manage plateaus, and how to address the psychological and behavioural aspects of sustainable weight loss.

The telehealth delivery model also removes a common barrier: the hassle of attending in-person appointments. Regular follow-up is critical to weight management success, and when follow-ups can be done via video from home or work, adherence to the monitoring schedule is dramatically higher.

Visit Weight Loss GP Australia →

Further Reading & Resources

TGA — Therapeutic Goods Administration

PBS — Pharmaceutical Benefits Scheme

RACGP — Royal Australian College of General Practitioners

New England Journal of Medicine — STEP and SURMOUNT trial data

Diabetes Australia — GLP-1 medication information

Heart Foundation — Cardiovascular risk and weight management